Key Stats for UnitedHealth Group Stock
- Past-Week Performance: -1.5%
- 52-Week Range: $234.6 to $606.4
- Current Price: $282.1
What Happened?
UnitedHealth Group (UNH) — the largest U.S. health insurer by revenue, serving nearly 50 million medical members — is that FY 2025 earnings from operations collapsed 41% to $19.0B as medical costs surged 19% and the medical care ratio, the share of premium revenue paid out in claims, blew out to 89.1% from 85.5%, dragging the stock from a 52-week high of $606.36 to $282.09.
Last January 27, UnitedHealth reported adjusted EPS of $16.35 for 2025, slightly above its own lowered expectations, while guiding 2026 adjusted EPS to greater than $17.75, an 8.6% recovery built on repricing across Medicare Advantage, Medicaid, and commercial insurance lines that management expects will expand UnitedHealth’s operating margin by 40 basis points.
The recovery’s central obstacle is Medicare Advantage, the government-funded private insurance program for Americans 65 and older that represents the company’s largest and most profitable segment, where UNH now expects 1.3M to 1.4M member losses in 2026 after prioritizing margin over volume during a fiercely competitive annual enrollment period.
CFO Wayne DeVeydt stated at the Barclays Global Healthcare Conference on March 10 that “based on the intrinsic value that we are currently trading at on a discount basis, there’s probably no better acquisition than ourselves right now,” signaling that the company intends to accelerate share buybacks in the second half of 2026 as it targets at least $18B in operating cash flow.
With $1.5B in planned AI investment in 2026, nearly $1B in AI-enabled cost reductions already underway, 800 new OptumRx pharmacy benefit clients onboarded for 2026 and 2027, and management committed to reaching a 40% debt-to-capital ratio before year-end, UNH is executing a multi-front recovery that hinges on whether Medicare funding rates, two pending criminal trials of the man accused of killing its insurance CEO, and rising medical cost trends allow the thesis enough runway to prove itself.
Wall Street’s Take on UNH Stock
The repricing cycle UNH executed across Medicare Advantage, Medicaid, and commercial lines in 2025 is now visible in the forward numbers: consensus estimates project EBIT recovering 24.1% to $23.5B in 2026, lifting operating margin from the 4.2% trough back to 5.3%.
That margin recovery is not assumed on revenue growth — 2026 consensus revenue actually contracts 1.1% to $442.5B — which means the entire improvement comes from medical cost discipline and the $1B in AI-enabled operating efficiencies management identified at the January 27 earnings call.
Fifteen analysts currently rate UNH a Buy, 6 an Outperform, 6 a Hold, and 2 a Sell, with a mean price target of $362.54 that implies 28.5% upside from $282.09, suggesting the Street still sees a recovery path even as the stock sits near a multi-year low.
The spread between the analyst low target of $255.00 and the high of $440.00 reflects precisely the two-sided risk in this story: the $255 floor corresponds to a scenario where 2027 Medicare Advantage rates finalize unfavorably and medical trend stays elevated at 10% or above, while the $440 ceiling prices in successful repricing and margin normalization above 6%.
What Does the Valuation Model Say?
TIKR’s mid-case valuation model targets $592.78 per share by December 31, 2030, implying 110.1% total return and a 16.7% annualized IRR from current levels, driven by mid-case EPS CAGR of 13.1% and net income margins expanding from 3.3% in 2025 to 5.0% by the forecast horizon.
The market is pricing UNH as if the 4.2% operating margin is permanent, but consensus already models a return to 5.3% in 2026 and 6.0% by 2028, with the operational lever being the deliberate shedding of 2.3M to 2.8M members who were diluting margins across Medicare, Medicaid, and commercial lines.
Accordingly, TIKR’s $592.78 mid-case target is underpinned by that margin normalization path, and the most direct supporting evidence is the $625M loss-contract reserve UNH booked in Q4 2025 for structurally unprofitable Optum contracts, nearly all of which management intends to exit or reprice for 2027, creating a dollar-for-dollar earnings tailwind.
Also, DeVeydt stated at the Barclays conference on March 10 that the company expects to be “more aggressive” in buybacks if the current stock dislocation persists, a signal that management at least believes the gap between price and intrinsic value is wide and closing.
The risk that breaks the TIKR model’s core assumption is the 2027 Medicare Advantage rate final notice: if CMS does not phase in or defer the ~3.3% combined risk-model and coding headwind flagged in the Advance Notice, another round of benefit cuts and member losses would push margin recovery further into 2028 and beyond.
The June 8 state murder trial of Luigi Mangione, accused of killing UnitedHealth CEO Brian Thompson, represents a near-term headline risk that could renew public scrutiny of the company’s claims practices and the number to watch alongside it is the Q1 2026 medical care ratio, which management guided should come in notably below the 88.8% full-year midpoint.
Should You Invest in UnitedHealth Group Incorporated?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up UNH stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track UnitedHealth Group Incorporated alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze UNH stock on TIKR for Free →
